Find syndicated market insights and custom brand analyses through our services offered in the gastroenterology market. Spherix’s independent research is conducted by our intelligence teams in collaboration with our proprietary network of gastroenterologists, patients, and leading KOLs.
Entyvio SC and Remsima SC have experienced noteworthy uptake since their launches in 2020 and are positioned for continued success...
Infliximab and adalimumab biosimilars continue to increase their presence in ulcerative colitis and Crohn’s disease therapy switching, while Entyvio SC...
Spherix Global Insights and Fraser Healthcare are partnering to shed light in this evolving landscape with a new service that...
With both steroid-based and advanced therapies poised for FDA approval in the near term, gastroenterologists’ general satisfaction with current eosinophilic...
